June 24, 2020 / 10:49 PM / 8 days ago

BRIEF-CSL To Buy Late-Stage Gene Therapy Candidate For Haemophilia B From Uniqure

June 25 (Reuters) - CSL Ltd:

* ACQUIRE LATE-STAGE GENE THERAPY CANDIDATE FOR HAEMOPHILIA B FROM UNIQURE

* UNIQURE WILL RECEIVE AN UPFRONT CASH PAYMENT OF US$450 MILLION

* UNIQURE TO COMPLETE PHASE 3 TRIAL AND SCALE UP MANUFACTURE FOR EARLY COMMERCIAL SUPPLY UNDER AGREED PLAN WITH CO

* UNIQURE WIL ALSO GET REGULATORY AND COMMERCIAL SALES MILESTONE PAYMENTS AND ROYALTIES

* UPON CLOSING DEAL, CSL WILL HAVE EXCLUSIVE GLOBAL RIGHT TO COMMERCIALISE AMT-061 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below